Mineralys Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About MLYS
All events for MLYS
All deals for MLYS
Financial Ratios
Financial Statements
MLYS vs Sector & Peers
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA. Website mineralystx.com
Headquarters Radnor, PA, US